Small molecule therapy for Macular Degeneration

Dwight Stambolian, MD, PhD
University of Pennsylvania (Philadelphia, PA)
Year Awarded:
2008
Grant Duration:
April 1, 2008 to June 30, 2010
Disease:
Macular Degeneration
Award Amount:
$100,000
Grant Reference ID:
M2008065
Award Type:
Standard
Award Region:
US Northeastern

Potential Therapy of Age-Related Macular Degeneration with Small Molecules

Summary

This project is looking for a small molecule which can penetrate the eye and diminish the eye inflammation that occurs in AMD. If successful, this small molecule can be administered at the earlier stages of AMD to halt progression to the later stages and eventual blindness. In order to identify such a molecule, we will screen a small molecule library and confirm its efficacy in a test tube before moving onto animal models.

Details

Current treatments for AMD do not restore vision. In wet AMD, treatment is directed at the terminal stages making it impossible to return vision to 20/20. For the dry type, the only treatment is a special vitamin preparation that is only effective in slowing the progression of AMD in some people. The researchers are investigating a small molecule that can penetrate the eye and diminish the eye inflammation that occurs in AMD. If successful, this small molecule could be administered in the earlier stages of AMD to halt disease progression and prevent blindness. They will identify such a molecule by screening a small molecule library and then will confirm its efficacy in a test tube before moving onto animal models.
Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.